REG - GENinCode PLC - Collaboration with University Clinic Dresden

GenincodeAnnouncement

15/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO3343Za&default-theme=true

RNS Number : 3343Z  GENinCode PLC  15 May 2023

GENinCode Plc

("GENinCode" or the "Company")

 

Collaboration with University Clinic Dresden for implementation of LIPID
inCode®

LIPID inCode® becomes first polygenic test for CVD implemented in Germany

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces its collaboration with
the University Clinic Dresden, Department of Internal Medicine and Department
of Human Genetics, based in Germany, to use its LIPID inCode® test in primary
care for the diagnosis of hypercholesterolemia (high levels of cholesterol)
and familial hypercholesterolemia ("FH"). LIPID inCode® is the first
polygenic product to be introduced in Germany to improve the diagnosis and
treatment of hypercholesterolemia to prevent cardiovascular disease ("CVD").
This new endeavour is based on a long-standing clinical research collaboration
of GENinCode with the Department of Medicine (Prof. Dr. S. Bornstein).

 

The University Clinic lipid centre treats over 6000 patients with lipid
disorders and constitutes the largest academic lipid apheresis centre
globally. In Germany, 60% of the population suffer from high levels of
cholesterol and it is estimated that over a quarter of a million of these
cases relate to FH(1). The collaboration also builds on the Transcampus
Initiative (https://www.kcl.ac.uk/transcampus)  between Technische
Universität in Dresden and Kings College London, providing a translational
model of best practice and patient care across borders.

 

LIPID inCode® testing will initially support the lipid centre in the region
of Saxony to deliver its preventative care plans to identify individuals at
risk of CVD. The lipid centre, will handle the regional roll-out of testing
and may extend testing to other regions of Germany. LIPID inCode® improves
the diagnosis and treatment of familial hypercholesterolemia with rapid
turnaround of test results to prevent the onset of CVD. It is also the first
commercially available polygenic test for CVD to be implemented in Germany.

 

The collaboration follows the positive results of the LIPID inCode® Dresden
clinical study and pilot. LIPID inCode® testing in the Saxony region will
cover a primary care population and community practice in the region. Testing
will diagnose patients with genetic disorders giving rise to high levels of
cholesterol, an important risk factor for the development of CVD. Improved
detection supports better treatment and preventative care.

 

In the Germany around 6 million people live with cardiovascular disease, which
causes 25% of all deaths annually, with the disease rate particularly high in
the region of Saxony(2). CVD can be reduced by identifying and treating
individuals at risk and the collaboration will focus on addressing CVD
prevention, including identifying individuals with hypercholesterolemia and
particularly those with FH.

 

FH is an inherited monogenic condition which affects an individual's ability
to regulate and remove cholesterol from their blood. For individuals suffering
with FH, it is important to lower cholesterol to healthy levels as early in
life as possible, often requiring medicines such as statins or more aggressive
treatment to help better control cholesterol levels.

 

GENinCode has a vision to assist clinicians and inform patients in
interpreting cardiovascular risk, and to improve public health using the
predictive capability of genomics. High genetic risk patients are assisted in
making lifestyle choices and can receive targeted treatment to improve
outcomes. Over the past 15 years GENinCode has made a substantial investment
in its research, bioinformatic data, technology, and product development to
assess disease risk, in order to help clinicians and patients prevent the
onset of CVD.

 

Matthew Walls, CEO of GENinCode PLC, said: "The collaboration with the
University Clinic in Dresden will focus on the use of Lipid inCode® testing
to identify patients at high risk of heart disease, the largest cause of death
in the Germany. The Dresden hub will handle regional testing and extend
testing to other regions of Germany for the adoption of our globally leading
polygenic test. We look forward to supporting the Dresden Lipid Centre in
reaching its plans to provide early diagnosis of patients with
hypercholesterolemia and prevent CVD."

 

Professor Stefan Bornstein, Chair and Director of Medicine of the University
Hospital and Transcampus Dean Kings College London, commented: "We are
delighted to collaborate with GENinCode to implement Lipid inCode® for the
diagnosis and treatment of hypercholesterolemia and familial
hypercholesterolemia. This collaboration marks a major step to improve our
primary care practice for the identification of FH sufferers and we welcome
this approach to work together with our UK colleagues as part of the German
and UK Transcampus programme to reduce the onset of cardiovascular disease."

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                      Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                Tel: 020 7933 8780 or genincode@walbrookpr.com

                                                                  (mailto:genincode@walbrookpr.com)
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

 

About University Clinic Dresden, Department of Medicine and Department of
Human Genetics:

The University Clinic Dresden, Department of Internal Medicine III, under the
direction of Clinic Director Prof. Dr. Stefan R. Bornstein - with more than
250 employees in medical, nursing, technical and administrative services as
well as in research - is one of the leading centres in Germany and Europe in
the field of treatment and research of diabetes mellitus type 1 and 2 as well
as its secondary diseases and lipid disorders. The clinic is home to the only
active islet cell transplantation programme in Germany at present, the
interdisciplinary vascular centre and the special outpatient clinics for
rheumatology, metabolism, diabetic foot, insulin pumps, angiology, nephrology,
endocrinology as well as the emergency room and the intensive care unit of
internal medicine. The department of human genetics has extensive expertise in
the analysis of common and rare genetic diseases and is also an integral part
of the cancer centre.

 

About cardiovascular disease (CVD)

CVD is a broad disease classification which encompasses conditions such as
coronary artery disease (causing angina, heart attacks, heart failure),
cerebrovascular disease (causing stroke, and some dementia), peripheral
vascular disease (causing limb ischemia, and some chronic kidney disease) and
venous thromboembolism. CVD is the leading cause of death and disability
worldwide accounting for one in every four deaths in the United States.
According to the US National Institutes of Health (NIH), by 2030, the global
cost of CVD is set to rise to US$1,044 billion, from approximately US$863
billion in 2010, and is both a major health issue and global economic
burden(3).

 

(1 (https://pubmed.ncbi.nlm.nih.gov/23703484/) )
(https://pubmed.ncbi.nlm.nih.gov/23703484/) Prevalence of dyslipidemia among
adults in Germany: results of the German Health Interview and Examination
Survey for Adults (DEGS 1)] - PubMed (nih.gov)
(https://pubmed.ncbi.nlm.nih.gov/23703484/)

(2) Regional Differences in the Prevalence of Cardiovascular Disease - PMC
(nih.gov) (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143789/)

(3) Data-driven quality improvement program to prevent hospitalisation and
improve care of people living with coronary heart disease: Protocol for a
process evaluation - PMC (nih.gov)
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110058/)

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUQCAUPWGCW